<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445965</url>
  </required_header>
  <id_info>
    <org_study_id>05-122</org_study_id>
    <secondary_id>MSKCC-05122</secondary_id>
    <nct_id>NCT00445965</nct_id>
  </id_info>
  <brief_title>Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer</brief_title>
  <official_title>Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8,
      can find tumor cells and carry tumor-killing substances to them without harming normal cells.
      This may be an effective treatment for central nervous system cancer or leptomeningeal
      metastases.

      PURPOSE: This phase II trial is studying the side effects and how well iodine I 131
      monoclonal antibody 3F8 works in treating patients with central nervous system cancer or
      leptomeningeal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine if intrathecal iodine I 131 monoclonal antibody 3F8 activity in patients with
           GD2-expressing central nervous system or leptomeningeal neoplasms is sufficiently
           promising (i.e., 6-month overall survival rate â‰¥ 25%) to warrant further study.

        -  Determine the response rate in patients treated with this drug.

        -  Determine the cumulative toxicities of this drug in these patients.

        -  Describe the effects of human-antimouse antibody on cerebrospinal fluid and serum
           pharmacokinetics in patients treated with this drug.

      OUTLINE: This is an open-label study.

      Patients receive intrathecal iodine I 131 monoclonal antibody 3F8 for dosimetry. Beginning
      approximately 1 week later, patients receive intrathecal iodine I 131 monoclonal antibody 3F8
      on day 1. Treatment intrathecal iodine I 131 monoclonal antibody 3F8 repeats weekly for up to
      4 courses in the absence of disease progression or unacceptable toxicity.

      Blood and cerebrospinal fluid samples are collected prior to and after administration of each
      course of study drug. Samples are analyzed to assess the intrathecal and blood
      pharmacokinetics of iodine I 131 monoclonal antibody 3F8 and serum human antimouse
      antibodies. Samples are also analyzed in tumor genetic studies.

      After completion of study treatment, patients are followed periodically for 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2006</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six-month overall survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>6 months</time_frame>
    <description>A &quot;response&quot; is defined as a patient being alive six months after their first treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cumulative toxicities</measure>
    <time_frame>1 year</time_frame>
    <description>Toxicities will be assessed via the NCI toxicity criteria (CTC 3.0).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Intraocular Melanoma</condition>
  <condition>Lung Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Neuroblastoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Retinoblastoma</condition>
  <condition>Sarcoma</condition>
  <condition>Small Intestine Cancer</condition>
  <arm_group>
    <arm_group_label>131I-3F8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a phase II single-arm open-label study that will define responses to therapy with weekly intrathecal 131I-3F8 in patients with central nervous system/leptomeningeal GD2-expressing disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 131 monoclonal antibody 3F8</intervention_name>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>131I-3F8</intervention_name>
    <description>Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.</description>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a histologically confirmed diagnosis of a malignancy known to
             expressGD2. Such tumors include medulloblastoma/primitive neuroectodermal tumor of the
             CNS, high grade astrocytomas, malignant glioma, neuroblastoma, retinoblastoma,
             ependymoma, rhabdoid tumors, sarcomas, melanoma or small cell lung carcinoma. For
             patients with other tumor types, GD2 expression must be confirmed by
             immunohistochemical staining and assessed by the Department of Pathology using prior
             frozen tissue, bone marrow or CSF cytology (send to Research Lab).

          -  Patients must have CNS/ leptomeningeal disease including high risk medulloblastoma, or
             a CNS/leptomeningeal malignancy which is refractory to conventional therapies, or for
             which no conventional therapy exists, OR a recurrent brain tumors with a predilection
             for leptomeningeal dissemination (medulloblastoma, PNET, rhabdoid tumor).

          -  Patients must have an absolute neutrophil count (ANC) &gt; 1000/ul and a platelet count &gt;
             50,000/ul.

          -  Patients may have active malignancy outside the central nervous system.

          -  Patients who have a programmable shunt will not be excluded.

          -  Both pediatric and adult patients of any age are eligible.

          -  Patients or a legal guardian will sign an informed consent form approved by the IRB
             and obtained by the Principal or a Co- Investigator before patient entry. Minors will
             provide assent.

        Exclusion Criteria:

          -  Patients with obstructive or symptomatic communicating hydrocephalus.

          -  Patients with an uncontrolled life-threatening infection.

          -  Patients who are pregnant: Pregnant women are excluded for fear of danger to the
             fetus. Therefore negative pregnancy test is required for all women of child-bearing
             age, and appropriate contraception is required during the study period.

          -  Patients who have received cranial or spinal irradiation less than 3 weeks prior to
             the start of this protocol.

          -  Patients who have received systemic chemotherapy (corticosteroids not included) less
             than 3 weeks prior to the start of this protocol.

          -  Severe major organ toxicity. Specifically, renal, cardiac, hepatic, pulmonary, and
             gastrointestinal system toxicity should all be less than or equal to grade 2. Patients
             with stable neurological deficits (because of their brain tumor) are not excluded.
             Patients with &lt;= 3 hearing loss are not excluded.

          -  Patients must have no rapidly progressing or deteriorating neurologic examination.

          -  Patients who have already received &gt;45 Gy to the craniospinal radiation or &gt;72 Gy
             focal brain radiation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Kramer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>adult supratentorial primitive neuroectodermal tumor (PNET)</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult subependymal giant cell astrocytoma</keyword>
  <keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
  <keyword>untreated childhood subependymal giant cell astrocytoma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>untreated childhood cerebellar astrocytoma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>childhood mixed glioma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood visual pathway glioma</keyword>
  <keyword>untreated childhood brain stem glioma</keyword>
  <keyword>untreated childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>untreated childhood visual pathway glioma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>extraocular retinoblastoma</keyword>
  <keyword>recurrent retinoblastoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>adult ependymoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>chondrosarcoma</keyword>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>stage III uterine sarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult desmoplastic small round cell tumor</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>childhood desmoplastic small round cell tumor</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>intraocular retinoblastoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <keyword>metastatic intraocular melanoma</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood pineoblastoma</keyword>
  <keyword>untreated childhood pineoblastoma</keyword>
  <keyword>adult pineal gland astrocytoma</keyword>
  <keyword>stage IIIA melanoma</keyword>
  <keyword>stage IIIB melanoma</keyword>
  <keyword>stage IIIC melanoma</keyword>
  <keyword>recurrent childhood anaplastic astrocytoma</keyword>
  <keyword>untreated childhood anaplastic astrocytoma</keyword>
  <keyword>recurrent childhood anaplastic oligoastrocytoma</keyword>
  <keyword>recurrent childhood anaplastic oligodendroglioma</keyword>
  <keyword>untreated childhood anaplastic oligoastrocytoma</keyword>
  <keyword>untreated childhood anaplastic oligodendroglioma</keyword>
  <keyword>recurrent childhood giant cell glioblastoma</keyword>
  <keyword>recurrent childhood glioblastoma</keyword>
  <keyword>untreated childhood giant cell glioblastoma</keyword>
  <keyword>untreated childhood glioblastoma</keyword>
  <keyword>recurrent childhood gliosarcoma</keyword>
  <keyword>untreated childhood gliosarcoma</keyword>
  <keyword>recurrent childhood gliomatosis cerebri</keyword>
  <keyword>untreated childhood gliomatosis cerebri</keyword>
  <keyword>childhood high-grade cerebellar astrocytoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Retinoblastoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Iodine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

